earn preview select biotech
earn around corner provid thought select larg mid-
cap biotech compani within coverag earn preview
celg addit upgrad mru discuss
downgrad discuss updat valuat price target glpg
follow finch ph iii ra data updat model adjust number
price target see tabl summaris chang page tend season light
given fewer sell day medicar donut hole believ could
exagger year part due moder price increas see gener
bake consensu number alreadi limit potenti major miss
howev lower likelihood signific beat re-ignit sector enthusiasm
expect continu relianc innov drive upsid especi
loom return drug price headlin elect approach expect
earn convers domin bd strategi among large-cap
regulatori path among mid/smid-cap glpg
outperform pt vs believ compani post better quarter
mani expect late rx data suggest substanti potenti beat key hiv drug
biktarvi estimate vs con epclusa vs help off-set weak across
much rest legaci hiv franchis truvada atripla genvoya descovi particular
like weak harvoni expens come season light could enabl bottom-lin beat estimate
vs overal expect quarter reaffirm commerci platform track
expect major focu new ceo day strateg initi though may
yet fulli form filgotinib regulatori plan continu see valu current
share price reflect littl potenti pipelin bd hiv life cycl success
sector perform pt vs expect gener in-lin quarter product
consensu number appear mostli reflect like q-o-q inventori flip ms franchis
though continu rx eros like due ocrevu cannib could lead tysabri come slightli
light vs con spinraza con est look slightli optimist est vs con
recal account sale remain hemophilia inventori could augment report top-lin
revenu number though mostli wash bottom line increment
margin item could help ep beat margin expect primari focu call though
compani post-aducanumab plan willing settl tecfidera ip major bd defend
sma franchis vs competit etc believ given long-term risk commerci
franchis pipelin clariti import investor becom construct
outperform pt vs less disconnect script analysi
cf product sale consensu last quarter trend still appear reason favor particularli
symdeko see modest beat vs con help compani continu
solid commerci path believ could enabl exceed sale guidanc
well consensu estimate vs con competitor data second set tripl
combo result way favor see limit downsid risk year
potenti quieter year could see eu reimburs develop signal pipelin
progress help drive addit share appreci
detail celg glpg mru continu backpag
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
earn preview select biotech
celg sector perform pt vs ozanimod re-fil track ipr defeat
recent ip settlement multipl outsid agenc recommend deal barrier
complet merger april sharehold vote gone make
quarter less relev celg stand-alone nonetheless expect in-lin revlimid
coupl slight beat abraxan pomalyst base rx analys enabl
slight bottom-lin beat vs con though medicar season may
exagger due expans donut hole
outperform pt vs given progress gene therapi pipelin
quarterli exondi sale less potenti stock-mov base run rate
expect exondi sale come in-lin slightli light vs con
function/ck durabl data microdystrophin solid casimersen dystrophin signal
continu believ emerg pipelin critic mass gene therapi
development/manufactur expertis compani ahead curv build
remain under-valued next updat regulatori updat microdystrophin
program competitor data dmd gene therapi program
sector perform vs outperform pt expect gener in-lin quarter
data jakafi itacitinib gvhd topic rux vitiligo year highlight
commerci expans opportun within hematolog dermatolog respect
though current stock level believ pipelin promis life cycl potenti
bake share follow increas past month
downgrad share sector perform chang pt anticip
quieter year continu see opportun long-term valu creation see full detail
outperform pt dmd product sale remain difficult predict given lumpi
order pattern even overal deceler growth translarna
emflaza believ product continu provid solid foundat data
key pipelin driver risdiplam earli may addit progress gt-aadc
gene therapi program -- continu see potenti near-term upsid
outperform pt vs eye month detail ph iii
regener nash result easl expect provid reassur around oca
safeti profil approv also expect in-lin perform quarter
continu gradual script growth/adopt help off-set season gross-to-net
potenti continu like share easl potenti fda panel/approv
sector perform pt return rx growth/scal stabil mavyret look
potenti beat assum major chang discount signific eros public
channel author gener assum continu ex-u growth
estimate could enabl increment beat hcv royalti vs con
share consider year-to-d key valuat upsid
view greater optim pipelin expect net posit data
rsv nash ph iia program start mid-year like take addit work
given respect trial design determin translat success differenti
product candid keep us sidelin
earn preview select biotech
glpg sector perform pt vs though quarterli number less relev glpg
take opportun updat model/valu base recent posit
data increas po filgotinib ra indic along
gener model updat increas pt look updat key
manta studi better gaug regulatori outcom potenti competit
mru outperform pt vs re-emerg bispecif key technolog
pair target modul data lead clinic program aml mcla-
breast cancer addit progress take opportun
upgrad mru outperform increas target believ promis
portfolio uniqu bispecif discovery/product technolog reflect
valuat see compel long-term buy opportun -- particularli share near
low ev see full detail
stat sell day vs fx eur/usd bp q-o-q unfavor usd
strength biggest potenti beat includ biktarvi con epclusa
con well oca con notabl miss includ
harvoni con genvoya con atripla con
spinraza con
new prior estim shown incom statement follow page
price rate adjust
earn preview select biotech
earn preview select biotech
estim mm except per share item estimatesconsensu taf earn preview select biotech
adjust hiv
base rx sale
increas
est account
increas po
filgotinib ra
indic
due posit
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit europe- international- antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
capit market estim compani report consensu
estim mm except per share item estimatesconsensu earn preview select biotech
increas out-year avonex est slightli lower tysabri est base rx data
account new share buy-back initi
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand vertex
earn preview select biotech
minor chang kalydeco orkambi symdeko go-forward sale base rx trend
slight reduct tripl combo revenu given updat regulatori timelin
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand celgen celg
earn preview select biotech
capit market estim compani report consensu
slightli increas otezla abraxan est slightli decreas pomalyst est base rx trend
adjust out-year revlimid model alreadi assum addit settlement
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand sarepta
earn preview select biotech
increas po casimersen follow posit express data
updat balanc sheet cash flow valu
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesjakafi earn preview select biotech
adjust olumi price est reflect rx trend decreas out-year ra growth drug due
decreas po olumi ad given evolv jak class safeti landscap
increas estim pemigatinib base price epidemiolog updat
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
estim mm except per share item estimatesconsensu earn preview select biotech
updat balanc sheet cash flow valu
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom intercept
earn preview select biotech
updat balanc sheet cash flow valu
updat ep multipl discount calcul pull onward
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva licens total revenu cost sales- research sell gener stock-bas total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand enanta
earn preview select biotech
increas mavyret est base solid rx growth trend
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end appendix
earn preview select biotech
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit europe- international- antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni/auth generic- unit states- europe- international- epclusa/auth generic- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- biktarvi unit europe- international- antivir includ vemlidi unit zydelig- product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv via dcf analysi discount rate termin growth rate
post-taf gener price target support outperform rate
risk rate price target risk includ gener hiv entrant competit hcv price pressur commerci
scientif complex cellular car-t therapi efficaci safeti risk pipelin product filgotinib
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit total oper gain sale incom incom expens net net pre-tax incom tax net net loss attribut non-controlling interest- net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf use discount rate termin growth rate appli
follow tecfidera patent expiri valuat support sector perform rate
risk rate price target risk rate price target includ competit gener price pressur
ms competit sma
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf analysi base busi discount rate
termin growth rate price target support outperform rate
risk rate price target risk includ lower expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand celg
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom net- interest expens incom expens net net pre-tax incom tax net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target base dcf analysi use discount rate termin growth rate beyond
revlimid cliff valuat justifi sector perform rate celg base propos acquisit
risk rate price target risk includ failur acquisit close share volatil
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys price target support outperform
risk rate price target risk includ slower-than-anticip growth commerci setback exondi
failur gain eu approv exondi failur success develop gain regulatori approv follow-on exon-
skip drug includ golodirsen casimersen clinic setback gene therapi program poor perform
confirmatori studi lead market remov increas patient discontinu
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom statement thousand except share royalties- net eu revenu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand earn preview select biotech
valuat risk
valuat price target base dcf discount futur cash flow annual termin
growth rate begin jakafi patent expiri probability-weight potenti favor strateg altern
price target support sector perform rate
risk rate price target downsid risk includ greater-than-expect slow jakafi use myelofibrosi
polycythemia vera inabl obtain regulatori approv pemigatinib itacitinib topic ruxolitinib failur extend
jakafi life cycl new competit entrant price pressur jakafi olumi emerg safeti concern
market product limit efficaci signal within earlier-stag pipelin upsid risk includ better expect
uptak jakafi olumi approv higher-dos olumi develop strategi meaning extend
jakafi life cycl potenti execut transform busi develop activ
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ slower-than-expect ex-u launch translarna dmd slower-than-
anticip growth emflaza sale regulatori pushback gt-aadc neg trial result sma
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva licens total revenu cost sales- research sell gener stock-bas total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva licens total revenu cost sales- research sell gener stock-bas total oper incom interest expense- interest incom net pre-tax incom tax provision- net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ failur gain approv nash psc new drug-rel safeti signal
emerg unexpect increas frequenc death liver injuri signal potenti drug-rel toxic challeng
control therapeut window trial real-world set pruritu unmanag cholesterol increas stagnant
growth pbc due label chang conservat among physician uncertainti epidemiolog restrict
reimburs competit agent
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys valuat support sector perform
risk rate price target risk includ competit hcv nash/pbc price pressur hcv potenti
safeti signal emerg poor efficaci futur studi
earn preview select biotech
galapago glpg thousand except per share royalties/profit split royalties- revenu sales- oper adjust short-term financi financi net pre-tax result per share outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount analys valuat support sector perform rate
risk rate price target risk includ emerg safeti issu high regulatori bar ra drug like filgotinib
limit interpret early-stag data
earn preview select biotech
mru incom statement amount thousand sales/royalti sales- revenu sales- oper net pre-tax tax expense- comprehens net incom per share non-gaap outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount convert usd eur/usd convers rate
analys price target support outperform rate assign specul risk qualifi given unpredict
futur revenu expens non-revenu gener statu stock price volatil could result substanti
upside/downsid swing anticip valuat
risk rate price target risk includ failur demonstr efficaci safeti signal emerg
competit potenti price pressur oncolog space
earn preview select biotech
